Gwak, Hye Sun Professor

Pharmaceutical Sciences/Division of Pharmacy/Industrial Pharmaceutical Science

곽혜선 프로필 사진
Hye Sun Gwak is a professor at College of Pharmacy and an authority on clinical pharmacogenomics and cardiovascular pharmacotherapy. She received Pharm.D. degree from the University of Iowa. She has been involved in research of the effects of single nucleotide polymorphisms of genes on the pharmacokinetic and pharmacodynamic characteristics of anticoagulants and antihypertensive drugs. Recently, she is developing risk scoring systems utilizing machine learning methods for effective and safe DOAC therapy. Currently, she is the president of the Korean College of Clinical Pharmacy. She has published around 200 papers, including 150 SCI papers. She has also been involved in book writing and editing and published books such as <Pharmacotherapy>, <Introductory Pharmacy Practice Experience>, and <Dispensing and Patients Counseling>.
  • Dean, The Graduate School of Clinical Biohealth/Dean, The Graduate School of Clinical & Public Health Convergence/Dean, The College of Pharmacy/Director, Center for Pharmacy Healthcare Communication/Director, Pharmaceutical and Bio-pharm Convergence Education Center
  • Pharmaceutical Science Building B #103
  • 02-3277-4376
  • Office hours
    • 수 3시30분-5시, 금10-12시
Research Record
  • Sleep-related adverse events of smoking cessation drugs: A network meta-analysis of randomized controlled trials Psychiatry Research, 2024, v.335, 115874
    SCIE SSCI Scopus dColl.
  • ABCG2 Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, v.17, 2513-2522
    SCIE Scopus dColl.
  • Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban Scientific Reports, 2023, v.13 no.1, 15967
    SCIE Scopus dColl.
  • Association between genetic polymorphisms in fibrinogen genes and bleeding risk in patients treated with direct oral anticoagulants ANNALS ACADEMY OF MEDICINE SINGAPORE, 2023, v.52 no.7, 340-347
    SCIE Scopus dColl.
  • Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States FRONTIERS IN PHARMACOLOGY, 2023, v.14, 1205624
    SCIE Scopus dColl.
  • Construction of a risk scoring system using clinical factors and RYR2 polymorphisms for bleeding complications in patients on direct oral anticoagulants FRONTIERS IN PHARMACOLOGY, 2023, v.14, 1290785
    SCIE Scopus dColl.
  • Correlation between PPARG Pro12Ala Polymorphism and Therapeutic Responses to Thiazolidinediones in Patients with Type 2 Diabetes: A Meta-Analysis Pharmaceutics, 2023, v.15 no.6, 1778
    SCIE Scopus dColl.
  • Effects of CYP3A4*22 polymorphism on trough concentration of tacrolimus in kidney transplantation: a systematic review and meta-analysis FRONTIERS IN PHARMACOLOGY, 2023, v.14, 1201083
    SCIE Scopus dColl.
  • Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients MEDICINA-LITHUANIA, 2023, v.59 no.2, 292
    SCIE Scopus dColl.
  • Interactive Associations between PPARγ and PPARGC1A and Bisphosphonate-Related Osteonecrosis of the Jaw in Patients with Osteoporosis Pharmaceuticals, 2023, v.16 no.7, 1035
    SCIE Scopus dColl.
  • Machine learning-based prediction of risk factors for abnormal glycemic control in diabetic cancer patients receiving nutrition support: a case–control study Hormones, 2023, v.22 no.4, 637-645
    SCIE Scopus dColl.
  • Novel Gene Polymorphisms for Stable Warfarin Dose in a Korean Population: Genome-Wide Association Study Biomedicines, 2023, v.11 no.8, 2308
    SCIE Scopus dColl.
  • Prediction of medication-related osteonecrosis of the jaws using machine learning methods from estrogen receptor 1 polymorphisms and clinical information FRONTIERS IN MEDICINE, 2023, v.10, 1140620
    SCIE Scopus dColl.
  • Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Cancers, 2023, v.15 no.10, 2810
    SCIE Scopus dColl.
  • A Risk Scoring System Utilizing Machine Learning Methods for Hepatotoxicity Prediction One Year After the Initiation of Tyrosine Kinase Inhibitors Frontiers in Oncology, 2022, v.12, 790343
    SCIE Scopus dColl.
  • Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-analysis British Journal of Clinical Pharmacology, 2022, v.88 no.3, 933-941
    SCIE Scopus dColl.
  • Association between Genetic Polymorphisms and Bleeding in Patients on Direct Oral Anticoagulants Pharmaceutics, 2022, v.14 no.9, 1889
    SCIE Scopus dColl.
  • Association between SLCO1B1 polymorphism and methotrexate-induced hepatotoxicity: a systematic review and meta-analysis ANTI-CANCER DRUGS, 2022, v.33 no.1, 75-79
    SCIE Scopus dColl.
  • Association of P450 Oxidoreductase Gene Polymorphism with Tacrolimus Pharmacokinetics in Renal Transplant Recipients: A Systematic Review and Meta-Analysis PHARMACEUTICS, 2022, v.14 no.2, 261
    SCIE Scopus dColl.
  • Associations of GNAS and RGS Gene Polymorphisms with the Risk of Ritodrine-Induced Adverse Events in Korean Women with Preterm Labor: A Cohort Study Pharmaceutics, 2022, v.14 no.6, 1220
    SCIE Scopus dColl.
  • Effect of ITPA Polymorphism on Adverse Drug Reactions of 6-Mercaptopurine in Pediatric Patients with Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis Pharmaceuticals, 2022, v.15 no.4, 416
    SCIE Scopus dColl.
  • Effects of CYP2D6 genotypes on Plasmodium vivax recurrence after primaquine treatment: A meta-analysis Travel Medicine and Infectious Disease, 2022, v.48, 102333
    SCIE Scopus dColl.
  • Genetic Factors of Renin-Angiotensin System Associated with Major Bleeding for Patients Treated with Direct Oral Anticoagulants PHARMACEUTICS, 2022, v.14 no.2, 231
    SCIE Scopus dColl.
  • Global Research Trends of Gender-Related Artificial Intelligence in Medicine Between 2001–2020: A Bibliometric Study Frontiers in Medicine, 2022, v.9, 868040
    SCIE Scopus dColl.
  • Proton pump inhibitor use and hearing loss in patients with type 2 diabetes: Evidence from a hospital-based case-control study and a population-based cohort study British Journal of Clinical Pharmacology, 2022, v.88 no.6, 2738-2746
    SCIE Scopus dColl.
  • Risk Scoring System for Vancomycin-Associated Acute Kidney Injury Frontiers in Pharmacology, 2022, v.13, 815188
    SCIE Scopus dColl.
  • Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis British Journal of Clinical Pharmacology, 2022
    SCIE Scopus dColl.
  • The Association between ABCG2 421C>A (rs2231142) Polymorphism and Rosuvastatin Pharmacokinetics: A Systematic Review and Meta-Analysis Pharmaceutics, 2022, v.14 no.3, 501
    SCIE Scopus dColl.
  • A systematic review and meta-analysis of angiotensin-converting enzyme inhibitor use and psoriasis incidence Scientific Reports, 2021, v.11 no.1, 10037
    SCIE Scopus dColl.
  • ABCA1 69C>T Polymorphism and the Risk of Type 2 Diabetes Mellitus: A Systematic Review and Updated Meta-Analysis Frontiers in Endocrinology, 2021, v.12, 639524
    SCIE Scopus dColl.
  • Analysis of risk factors for hepatotoxicity induced by immune checkpoint inhibitors Journal of Immunotherapy, 2021 , 16-21
    SCIE Scopus dColl.
  • Article machine learning approaches to predict hepatotoxicity risk in patients receiving nilotinib Molecules, 2021, v.26 no.11, 3300
    SCIE Scopus dColl.
  • Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis CLINICAL THERAPEUTICS, 2021, v.43 no.5, 836-
    SCIE Scopus dColl.
  • Association between ABCA1 Gene Polymorphisms and Plasma Lipid Concentration: A Systematic Review and Meta-Analysis JOURNAL OF PERSONALIZED MEDICINE, 2021, v.11 no.9, 883
    SCIE Scopus dColl.
  • Association between ADCY9 Gene Polymorphisms and Ritodrine Treatment Outcomes in Patients with Preterm Labor PHARMACEUTICS, 2021, v.13 no.10, 1653
    SCIE Scopus dColl.
  • Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis JOURNAL OF PERSONALIZED MEDICINE, 2021, v.11 no.7, 677
    SCIE Scopus dColl.
  • Association between attention deficit hyperactivity disorder and aggression subscales in adolescents Brain and Behavior, 2021, v.11 no.3
    SCIE Scopus dColl.
  • Association between statin use and sensorineural hearing loss in type 2 diabetic patients: A hospital-based study Pharmaceuticals, 2021, v.14 no.11, 1076
    SCIE Scopus dColl.
  • Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials PHARMACEUTICALS, 2021, v.14 no.11, 1198
    SCIE Scopus dColl.
  • Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers JOURNAL OF PERSONALIZED MEDICINE, 2021, v.11 no.9, 862
    SCIE Scopus dColl.
  • Gene Polymorphisms of the Renin-Angiotensin System and Bleeding Complications of Warfarin: Genetic-Based Machine Learning Models PHARMACEUTICALS, 2021, v.14 no.8, 824
    SCIE Scopus dColl.
  • Influence of C Upsilon P2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis JOURNAL OF PERSONALIZED MEDICINE, 2021, v.11 no.7, 617
    SCIE Scopus dColl.
  • Machine learning approaches for predicting bisphosphonate-related osteonecrosis in women with osteoporosis using vegfa gene polymorphisms Journal of Personalized Medicine, 2021, v.11 no.6, 541
    SCIE Scopus dColl.
  • Risk Scoring System of Mortality and Prediction Model of Hospital Stay for Critically Ill Patients Receiving Parenteral Nutrition HEALTHCARE, 2021, v.9 no.7, 853
    SCIE SSCI Scopus dColl.
  • Short-term exposure to air pollution and hospital admission for pneumonia: a systematic review and meta-analysis Environmental Health: A Global Access Science Source, 2021 , 6
    SCIE Scopus dColl.
  • Smartphone Addiction and Anxiety in Adolescents - A Cross-sectional Study AMERICAN JOURNAL OF HEALTH BEHAVIOR, 2021, v.45 no.5, 895-901
    SSCI dColl.
  • TGF-β1 polymorphism increases the risk of bleeding complications in patients on oral anticoagulant after cardiac valve replacement Heart and Vessels, 2021, v.36 no.12, 1885-1891
    SCIE Scopus dColl.
  • 국내 허가사항에 반영된 약물 유전정보 분석 한국임상약학회지, 2021, v.31 no.1, 21-26
    KCI dColl.
  • Association Between Glutathione-S-Transferase Gene Polymorphisms and Responses to Tyrosine Kinase Inhibitor Treatment in Patients with Chronic Myeloid Leukemia: A Meta-analysis TARGETED ONCOLOGY, 2020, v.15 no.1, 47-54
    SCIE Scopus dColl.
  • Association between preoperative use of antithrombotic medications and intraoperative transfusion in older patients undergoing cancer surgery ASIAN JOURNAL OF SURGERY, 2020, v.43 no.5, 585-592
    SCIE Scopus dColl.
  • Association of pre-operative medication use with unplanned 30-day hospital readmission after surgery in oncology patients receiving comprehensive geriatric assessment AMERICAN JOURNAL OF SURGERY, 2020, v.219 no.6, 963-968
    SCIE Scopus dColl.
  • Clinical and Laboratory Features of Pediatric Patients with COVID-19: Systematic Review and Meta-analysis 한국임상약학회지, 2020, v.30 no.4, 270-278
    KCI dColl.
  • Clinical manifestations and perinatal outcomes of pregnant women with COVID-19: a systematic review and meta-analysis Scientific Reports, 2020, v.10 no.1, 18126
    SCIE Scopus dColl.
  • Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis Scientific Reports, 2020, v.10 no.1, 17390
    SCIE Scopus dColl.
  • Effects of Citrulline Supplementation on Body Weight in Patients With Hepatobiliary Pancreatic Surgery Nutrition in Clinical Practice, 2020, v.35 no.2, 323-330
    SCIE Scopus dColl.
  • Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects MOLECULAR GENETICS & GENOMIC MEDICINE, 2020, v.8 no.5, e1201
    SCIE Scopus dColl.
  • Effects of pharmacist interventions on reducing prescribing errors of investigational drugs in oncology clinical trials JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, v.26 no.1, 29-35
    SCIE Scopus dColl.
  • Effects ofKCNMB2gene polymorphisms on ritodrine therapy outcomes in women with preterm labor PHARMACOGENETICS AND GENOMICS, 2020, v.30 no.6, 124-130
    SCIE Scopus dColl.
  • Efficacy and safety of clopidogrel versus prasugrel and ticagrelor for coronary artery disease treatment in patients with CYP2C19 LoF alleles: a systemic review and meta-analysis British Journal of Clinical Pharmacology, 2020, v.86 no.8, 1489-1498
    SCIE Scopus dColl.
  • Factors Associated With Voriconazole Concentration in Pediatric Patients Therapeutic drug monitoring, 2020, v.42 no.6, 866-871
    SCIE Scopus dColl.
  • Factors Influencing Imatinib-Induced Hepatotoxicity CANCER RESEARCH AND TREATMENT, 2020, v.52 no.1, 181-188
    SCIE Scopus KCI dColl.
  • Factors affecting high-grade hepatotoxicity of tyrosine kinase inhibitors in cancer patients: a multi-center observational study European Journal of Clinical Pharmacology, 2020, v.76 no.8, 1183-1191
    SCIE Scopus dColl.
  • Genotype-guided warfarin dosing may benefit patients with mechanical aortic valve replacements: randomized controlled study Scientific Reports, 2020, v.10 no.1, 6988
    SCIE Scopus dColl.
  • Health Behaviors Associated with Aggression in Korean Adolescents: Data from 2 Cross-sectional Studies AMERICAN JOURNAL OF HEALTH BEHAVIOR, 2020, v.44 no.2, 271-282
    SSCI dColl.
  • Influence of CYP2C9 and CYP2A6 on plasma concentrations of valproic acid: a meta-analysis European Journal of Clinical Pharmacology, 2020, v.76 no.8, 1053-1058
    SCIE Scopus dColl.
  • Influence of GRK5 gene polymorphisms on ritodrine efficacy and adverse drug events in preterm labor treatment Scientific Reports, 2020, v.10 no.1, 1351
    SCIE Scopus dColl.
  • Low cyclosporine concentrations in children and time to acute graft versus host disease BMC PEDIATRICS, 2020, v.20 no.1
    SCIE Scopus dColl.
  • Population Pharmacokinetics of Sulindac and Genetic Polymorphisms of FMO3 and AOX1 in Women with Preterm Labor Pharmaceutical Research, 2020, v.37 no.3, 44
    SCIE Scopus dColl.
  • Risk factors for sodium overcorrection in non-hypovolemic hyponatremia patients treated with tolvaptan European Journal of Clinical Pharmacology, 2020, v.76 no.5, 723-729
    SCIE Scopus dColl.
  • The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis Scientific Reports, 2020, v.10 no.1, 3658
    SCIE Scopus dColl.
  • The impact of drug interactions on adverse effects of oral oxycodone in male geriatric patients Journal of Clinical Pharmacy and Therapeutics, 2020, v.45 no.5, 976-982
    SCIE Scopus dColl.
  • Vancomycin pharmacokinetics in critically ill neonates receiving extracorporeal membrane oxygenation EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2020, v.27 no.E1, E25-E29
    SCIE Scopus dColl.
  • APOB gene polymorphisms may affect the risk of minor or minimal bleeding complications in patients on warfarin maintaining therapeutic INR EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, v.27 no.10, 1542-1549
    SCIE Scopus dColl.
  • Association between HNF4A mutations and bleeding complications in patients with stable international normalized ratio Pharmacogenetics and genomics, 2019, v.29 no.8, 200-206
    Scopus dColl.
  • Association between VEGFA gene polymorphisms and bleeding complications in patients maintaining therapeutic international normalized ratio PHARMACOGENOMICS, 2019, v.20 no.9, 659-667
    SCIE Scopus dColl.
  • Association between anxiety and aggression in adolescents: a cross-sectional study BMC PEDIATRICS, 2019, v.19, 115
    SCIE Scopus dColl.
  • Comparisons of doxycycline solution with talc slurry for chemical pleurodesis and risk factors for recurrence in South Korean patients with spontaneous pneumothorax EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2019, v.26 no.5, 275-279
    SCIE Scopus dColl.
  • Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study British Journal of Clinical Pharmacology, 2019, v.85 no.8, 1719-1727
    SCIE Scopus dColl.
  • Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, v.105 no.6, 1477-1491
    SCIE Scopus dColl.
  • Effects of PDE4 gene polymorphisms on efficacy and adverse drug events of ritodrine therapy in preterm labor patients: a prospective observational study EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, v.75 no.10, 1379-1386
    SCIE Scopus dColl.
  • Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses CARDIOVASCULAR THERAPEUTICS, 2019 , 1813747
    SCIE Scopus dColl.
  • Effects of cyclic parenteral nutrition on parenteral nutrition-associated cholestasis in newborns ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, 2019, v.28 no.1, 42-48
    SCIE Scopus dColl.
  • Effects of proton pump inhibitor use on risk of Clostridium difficile infection: a hospital cohort study Journal of Gastroenterology, 2019, v.54 no.12, 1052-1060
    SCIE Scopus dColl.
  • Genetic variations in the transcription factors GATA4 and GATA6 and bleeding complications in patients receiving warfarin therapy DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, v.13, 1717-1727
    SCIE Scopus dColl.
  • Risk factors associated with the incidence and time to onset of lapatinib-induced hepatotoxicity Breast Cancer Research and Treatment, 2019, v.178 no.1, 239-244
    SCIE Scopus dColl.
  • Risk factors for neutropenia and febrile neutropenia following prophylactic pegfilgrastim Asia-Pacific Journal of Clinical Oncology, 2019, v.15 no.4, 231-237
    SCIE Scopus dColl.
  • 암 환자에서의 임상시험용 의약품 처방 오류 분석 병원약사회지, 2019, v.36 no.3, 366~373
    KCI dColl.
  • Association between MKRN3 and LIN28B polymorphisms and precocious puberty BMC Genetics, 2018, v.19 no.1, 47
    SCIE Scopus dColl.
  • Association of pre-operative medication use with post-surgery mortality and morbidity in oncology patients receiving comprehensive geriatric assessment AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2018, v.30 no.10, 1177-1185
    SCIE Scopus dColl.
  • Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity JOURNAL OF CLINICAL PHARMACOLOGY, 2018, v.58 no.2, 263-268
    SCIE Scopus dColl.
  • Factors affecting crizotinib-induced hepatotoxicity in non-small cell lung cancer patients Medical Oncology, 2018, v.35 no.12, 154
    SCIE Scopus dColl.
  • Factors affecting time to reach and recover from gefitinib-induced hepatotoxicity ANTI-CANCER DRUGS, 2018, v.29 no.5, 471-476
    SCIE Scopus dColl.
  • Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses GENE, 2018, v.641, 68-73
    SCIE Scopus dColl.
  • Preoperative medication use and its association with postoperative length of hospital stay in surgical oncology patients receiving comprehensive geriatric assessment GERIATRICS & GERONTOLOGY INTERNATIONAL, 2018, v.18 no.1, 12-19
    SCIE SSCI dColl.
  • Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study BMC CANCER, 2018, v.18, 988
    SCIE Scopus dColl.
  • Risk factors of opioid-induced adverse reactions in elderly male outpatients of Korea Veterans Hospital BMC GERIATRICS, 2018, v.18, 293
    SCIE SSCI Scopus dColl.
  • Smartphone addiction risk and daytime sleepiness in Korean adolescents JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2018, v.54 no.7, 800-806
    SCIE Scopus dColl.
  • 조혈모세포 이식을 받은 소아 환자에서 cyclosporine의 집단 약동학 분석 한국임상약학회지, 2018, v.28 no.1, 24~29
    KCI dColl.
  • Association between CACNA1C gene polymorphisms and ritodrine-induced adverse events in preterm labor patients European Journal of Clinical Pharmacology, 2017, v.73 n.7, 1-6
    SCIE Scopus dColl.
  • Association between ß2-adrenergic receptor gene polymorphisms and adverse events of ritodrine in the treatment of preterm labor: A prospective observational study BMC Genetics, 2017, v.18 no.1
    SCIE Scopus dColl.
  • Attitudes to proposed assessment of pharmacy skills in Korean pharmacist licensure examination Journal of educational evaluation for health professions, 2017, v.14, 6
    Scopus dColl.
  • Effects of adrenal androgen levels on bone age advancement in prepubertal children: Using the Ewha birth and growth cohort study Journal of Korean Medical Science, 2017, v.32 no.6, 968-973
    SCIE Scopus KCI dColl.
  • Elevated Metabolites of Steroidogenesis and Amino Acid Metabolism in Preadolescent Female Children With High Urinary Bisphenol A Levels: A High-Resolution Metabolomics Study TOXICOLOGICAL SCIENCES, 2017, v.160 no.2, 371-385
    SCIE Scopus dColl.
  • Factors for time to trastuzumab-induced cardiotoxicity in breast cancer patients Medical Oncology, 2017, v.34 no.12, 199
    SCIE Scopus dColl.
  • Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, v.236, 393-397
    SCIE Scopus dColl.
  • New Anticoagulants for the Prevention and Treatment of Venous Thromboembolism BIOMOLECULES & THERAPEUTICS, 2017, v.25 no.5, 461-470
    SCIE Scopus KCI dColl.
  • Outcomes with perioperative fat emulsions containing omega-3 fatty acid: A meta-analysis of randomized controlled trials American Journal of Health-System Pharmacy, 2017, v.74 no.12, 904-918
    SCIE Scopus dColl.
  • 제 2형 당뇨병 환자에서 Metformin과 병용 시 Dapagliflozin과 Sitagliptin의 효능 비교 한국임상약학회지, 2017, v.27 no.2, 99~104
    KCI dColl.
  • Association of inflammatory gene polymorphisms with mechanical heart valve reoperation SPRINGERPLUS, 2016, v.5
    SCIE Scopus dColl.
  • Association of pre-operative medication use with post-operative delirium in surgical oncology patients receiving comprehensive geriatric assessment BMC GERIATRICS, 2016, v.16
    SCIE SSCI Scopus dColl.
  • Evaluation of the predictors of readmission in Korean patients with heart failure Journal of Clinical Pharmacy and Therapeutics, 2016, v.42 no.1
    SCIE Scopus dColl.
  • 암환자의 정맥혈전색전증 치료에서 rivaroxaban과 dalteparin의 출혈 부작용 비교 한국임상약학회지, 2016, v.26 no.3, 195~200
    KCI dColl.
  • Application of Monodirectional Janus Patch to Oromucosal Delivery System Advanced Healthcare Materials, 2015, 8 SEP 2015
    SCIE Scopus dColl.
  • Association of inflammatory gene polymorphisms with the prosthetic heart valve reoperation PHARMACOTHERAPY, 2015, v.35 no.11, E178-E178
    SCIE Scopus dColl.
  • Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves European Journal of Clinical Pharmacology, 2015, v.71 no.10, 1229-1236
    SCIE Scopus dColl.
  • Effects of pregnane X receptor genetic polymorphisms on stable warfarin doses Journal of Cardiovascular Pharmacology and Therapeutics, 2015, v.20 no.6, 532-538
    SCIE Scopus dColl.
  • Effects of single nucleotide polymorphisms in c-Myc on stable warfarin doses in patients with cardiac valve replacements PHARMACOGENOMICS, 2015, v.16 no.10, 1101-1108
    SCIE Scopus dColl.
  • INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation International Journal of Clinical Pharmacy, 2015, 12 Jun 2015
    Scopus dColl.
  • Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves PHARMACOGENOMICS JOURNAL, 2015, v.15 no.1, 33-37
    SCIE Scopus dColl.
  • Impact of NQO1 variants on stable warfarin doses in Korean patients with mechanical cardiac valves PHARMACOTHERAPY, 2015, v.35 no.11, E206-E207
    SCIE Scopus dColl.
  • Impact of pediatric pharmacist interventions in general pediatric ward in Korea PHARMACOTHERAPY, 2015, v.35 no.11, E251-E251
    SCIE Scopus dColl.
  • Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves Cardiovascular Therapeutics, 2015, v.33 no.6, 324-328
    SCIE Scopus dColl.
  • Influence of UDP-glucuronosyltransferase polymorphisms on warfarin dosing requirement PHARMACOTHERAPY, 2015, v.35 no.11, E207-E207
    SCIE Scopus dColl.
  • Relationship of serum 25-Hydroxyvitamin D (25[OH]D) levels and components of metabolic syndrome in prepubertal children Nutrition, 2015, v.31 no.42320, 1324-1327
    SCIE Scopus dColl.
  • The preventive effect of breast-feeding for longer than 6 months on early pubertal development among children aged 7-9 years in Korea Public Health Nutrition, 2015, v.18 no.18, 3300-3307
    SCIE Scopus dColl.
  • 제2형 당뇨병 환자에서 Metformin/Dipeptidyl Peptidase-4 저해제 병용요법과Metformin/Sulfonylurea 병용요법간의 효과에 대한 비교 연구 한국임상약학회지, 2015, v.25 no.2, 74-79
    KCI dColl.
  • 6년제 약대 학제시스템 만족도에 영향을 미치는 요인 분석 및 향후 전략 한국임상약학회지, 2014, 제24권 4호, 288-295
    KCI dColl.
  • Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, v.39 no.3, 314-318
    SCIE Scopus dColl.
  • Combined effects of hepatocyte nuclear factor 4α and constitutive androstane receptor on stable warfarin doses Pharmacogenetics and Genomics, 2014, v.25 no.1, 38-40
    SCIE Scopus dColl.
  • Development of clinical pharmacy services for intensive care units in Korea SpringerPlus, 2014, v.3 no.1, 1-7
    SCIE Scopus dColl.
  • EFFECT OF BIOCOMPATIBLE PERITONEAL DIALYSIS SOLUTION ON RESIDUAL RENAL FUNCTION: A SYSTEMATIC REVIEW OF RANDOMIZED CONTROLLED TRIALS PERITONEAL DIALYSIS INTERNATIONAL, 2014, v.34 no.7, 724-731
    SCIE Scopus dColl.
  • Effects of Single-Nucleotide Polymorphisms of FMO3 and FMO6 Genes on Pharmacokinetic Characteristics of Sulindac Sulfide in Premature Labor DRUG METABOLISM AND DISPOSITION, 2014, v.42 no.1, 40-43
    SCIE Scopus dColl.
  • Effects of inflammatory cytokine gene polymorphisms on warfarin maintenance doses in Korean patients with mechanical cardiac valves ARCHIVES OF PHARMACAL RESEARCH, 2014, v.37 no.6, 752-759
    SCIE KCI Scopus dColl.
  • Effects of β2-adrenergic receptor gene polymorphisms on ritodrine therapy in pregnant women with preterm labor: Prospective follow-up study International Journal of Molecular Sciences, 2014, v.15 no.7, 12885-12894
    SCIE Scopus dColl.
  • Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, v.71 no.2, 122-127
    SCIE Scopus dColl.
  • Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2014, v.39 no.4, 237-242
    SCIE Scopus dColl.
  • 고등학생의 공격적 성향과 건강 행태에 관한 연구 한국임상약학회지, 2014, 제24권 2호, 144-153
    KCI dColl.
  • 습기주의 약품의 산제 투약 시 손실분의 분석과 개선 방안 병원약사회지, 2014, 제31권 6호, 1092-1098
    KCI후보 dColl.
  • 제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구 한국임상약학회지, 2014, 제24권 3호, 193-198
    KCI dColl.
  • 출생 체중 1 kg 미만의 초 극소 저 체중 출생아에서침습성 진균 감염증에 대한 Fluconazole 예방 요법의 효과 분석 병원약사회지, 2014, 제31권 4호, 919-927
    KCI후보 dColl.
  • [학술지논문] Health Behaviors Associated with Aggression in Korean Adolescents: Data from 2 Cross-sectional Studies AMERICAN JOURNAL OF HEALTH BEHAVIOR, 2020, v.44 no.2 , 271-282
    SSCI
Courses
  • 2024-2nd

    • Pharmacotherapeutics I 강의 계획서 상세보기

      • Subject No 36215Class No 01
      • 4Year ( 3Credit , 3Hour) Wed 2~2 (PHM-A104) , Thu 5~5 (POSCO551)
      • Major Requisite
    • Pharmacotherapeutics I 강의 계획서 상세보기

      • Subject No 36215Class No 02
      • 4Year ( 3Credit , 3Hour) Wed 3~3 (PHM-A104) , Fri 4~4 (PHM-A104)
      • Major Requisite
    • Pharmacotherapeutics I 강의 계획서 상세보기

      • Subject No 36215Class No 03
      • 4Year ( 3Credit , 3Hour) Thu 2~2 (PHM-A100-1) , Fri 3~3 (PHM-A104)
      • Major Requisite
    • Design of Clinical Research & Research methodology

    • Design of Clinical Research & Research methodology 강의 계획서 상세보기

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Mon 8~9 (POSCO-451)
  • 2024-1st

    • Pharmacotherapeutics Ⅱ 강의 계획서 상세보기

      • Subject No 37135Class No 01
      • 5Year ( 3Credit , 3Hour) Mon 5~5 (PHM-A104) , Wed 5~5 (PHM-A404)
      • Major Requisite,Language Changed
    • Pharmacotherapeutics Ⅱ 강의 계획서 상세보기

      • Subject No 37135Class No 02
      • 5Year ( 3Credit , 3Hour) Mon 3~3 (PHM-A100-1) , Thu 3~3 (PHM-A404)
      • Major Requisite,Language Changed
    • Pharmacotherapeutics Ⅱ 강의 계획서 상세보기

      • Subject No 37135Class No 03
      • 5Year ( 3Credit , 3Hour) Tue 3~3 (POSCO552) , Thu 5~5 (PHM-A100-1)
      • Major Requisite,Language Changed
    • Drug Literature Evaluation and Clinical Research Design 강의 계획서 상세보기

      • Subject No 37139Class No 01
      • 5Year ( 1.5Credit , 1.5Hour) Thu 2~2 (PHM-A404)
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 01
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 02
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 03
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 04
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 05
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 06
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Honors research

    • Pharmacotherapy in Cardiovascular & Respiratory Disorders

    • Clinical Pharmacokinetics/Clinical Pharmacogenomics

    • Pharmacotherapy in Cardiovascular & Respiratory Disorders 강의 계획서 상세보기

      • Subject No CP531Class No 01
      • Year ( 3Credit , 3Hour) Mon 8~9 (POSCO-451)
    • Clinical Pharmacokinetics/Clinical Pharmacogenomics 강의 계획서 상세보기

      • Subject No CP650Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (POSCO-451)
  • 2023-2nd

  • 2023-1st

  • 2022-2nd

    • Pharmacotherapeutics I

      • Subject No 36215Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 3~3 (PHM-A104) , Fri 3~3 (PHM-A104)
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 02
      • 4Year ( 3Credit , 3Hour) Mon 2~2 (PHM-A404) , Thu 5~5 (PHM-A104)
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 03
      • 4Year ( 3Credit , 3Hour) Wed 4~4 (PHM-A404) , Fri 4~4 (PHM-A104)
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 04
      • 4Year ( 3Credit , 3Hour) Wed 4~4 (PHM-A404) , Fri 4~4 (PHM-A104)
      • Major Requisite
    • Advanced Pharmacy Practice and Research Ⅱ

      • Subject No 37155Class No 01
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Honors research

    • Drug Study Design and Literature Evaluation

      • Subject No G16904Class No 01
      • Year ( 3Credit , 3Hour) Mon 5~6 (PHM-)
    • Design of Clinical Research & Research methodology

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Mon 8~9 (ECC-)
  • 2022-1st

    • First-Year Seminar

    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 01
      • 5Year ( 3Credit , 3Hour) Mon 4~4 , Wed 4~4
      • Major Requisite
    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 02
      • 5Year ( 3Credit , 3Hour) Mon 5~5 , Wed 5~5
      • Major Requisite
    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 03
      • 5Year ( 3Credit , 3Hour) Tue 4~4 , Thu 3~3
      • Major Requisite
    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 04
      • 5Year ( 3Credit , 3Hour) Tue 4~4 , Thu 3~3
      • Major Requisite
    • Drug Literature Evaluation and Clinical Research Design

      • Subject No 37139Class No 01
      • 5Year ( 1.5Credit , 1.5Hour) Tue 6~6
    • Drug Literature Evaluation and Clinical Research Design

      • Subject No 37139Class No 02
      • 5Year ( 1.5Credit , 1.5Hour) Tue 6~6
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 01
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 02
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 03
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 04
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 05
      • 6Year ( 4Credit , 200Hour)
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
    • Seminar for Pharmaceutical Sciences III

      • Subject No G16849Class No 01
      • Year ( 3Credit , 3Hour) Thu 7~8 (-)
    • Seminar for Pharmaceutical Sciences Ⅲ

      • Subject No G18240Class No 01
      • Year ( 3Credit , 3Hour) Thu 7~8 (-)
    • Pharmacotherapy in Cardiovascular & Respiratory Disorders

      • Subject No CP531Class No 01
      • Year ( 3Credit , 3Hour) Mon 8~9 (ECC-)
    • Clinical Pharmacokinetics/Clinical Pharmacogenomics

      • Subject No CP650Class No 01
      • Year ( 3Credit , 3Hour) Tue 8~9 (ECC-)
  • 2021-2nd

    • Pharmacotherapeutics I

      • Subject No 36215Class No 01
      • 4Year ( 3Credit , 3Hour) Tue 3~3 , Fri 3~3
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 02
      • 4Year ( 3Credit , 3Hour) Tue 4~4 , Thu 5~5
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 03
      • 4Year ( 3Credit , 3Hour) Wed 4~4 , Fri 4~4
      • Major Requisite
    • Pharmacotherapeutics I

      • Subject No 36215Class No 04
      • 4Year ( 3Credit , 3Hour) Wed 4~4 , Fri 4~4
      • Major Requisite
    • Advanced Pharmacy Practice and Research I

      • Subject No 37154Class No 01
      • 6Year ( 4Credit
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
    • Drug Study Design and Literature Evaluation

      • Subject No G16904Class No 01
      • Year ( 3Credit , 3Hour) Wed 5~6 (PHM-)
    • Design of Clinical Research & Research methodology

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Design of Clinical Research & Research methodology

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Design of Clinical Research & Research methodology

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Design of Clinical Research & Research methodology

      • Subject No CP529Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
  • 2021-1st

    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 01
      • 5Year ( 3Credit , 3Hour) Tue 2~2 , Fri 3~3
      • Major Requisite
    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 02
      • 5Year ( 3Credit , 3Hour) Mon 4~4 , Wed 2~2
      • Major Requisite
    • Pharmacotherapeutics Ⅱ

      • Subject No 37135Class No 03
      • 5Year ( 3Credit , 3Hour) Tue 3~3 , Thu 4~4
      • Major Requisite
    • Drug Literature Evaluation and Clinical Research Design

      • Subject No 37139Class No 01
      • 5Year ( 1.5Credit , 1.5Hour) Wed 3~3
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 01
      • 6Year ( 4Credit
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 02
      • 6Year ( 4Credit , 0Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 03
      • 6Year ( 4Credit , 0Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 04
      • 6Year ( 4Credit , 0Hour)
      • Major Requisite
    • Hospital Pharmacy Practice II

      • Subject No 37151Class No 05
      • 6Year ( 4Credit , 0Hour)
      • Major Requisite
    • Honors research

      • Subject No 37803Class No 01
      • 4Year ( 1Credit , 1Hour)
    • Pharmaceutical Care in Cardiovascular and Endocrine Disorders

      • Subject No G16865Class No 01
      • Year ( 3Credit , 3Hour) Thu 5~6
    • Pharmacotherapy in Endocrinologic & Gastrointestinal Disorders

      • Subject No CP539Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Pharmacotherapy in Endocrinologic & Gastrointestinal Disorders

      • Subject No CP539Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Pharmacotherapy in Endocrinologic & Gastrointestinal Disorders

      • Subject No CP539Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
    • Pharmacotherapy in Endocrinologic & Gastrointestinal Disorders

      • Subject No CP539Class No 01
      • Year ( 3Credit , 3Hour) Wed 8~9 (ECC-)
Academic Background

The University of Iowa Pharm.D.(약학과)